Statement Of Cash Flows [Abstract]

Mithra Pharmaceuticals S.A. - Filing #3183078

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	—	59,620,000 EUR	59,620,000 EUR	—	116,875,000 EUR	116,875,000 EUR	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories	—	6,873,000 EUR	—	—	8,470,000 EUR	—	—
Adjustments for share-based payments	—	1,983,000 EUR	—	—	1,065,000 EUR	—	—
Cash flows from (used in) operating activities	—	56,819,000 EUR	—	—	76,788,000 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	169,000 EUR	—	—	- EUR	—	—
Purchase of property, plant and equipment, classified as investing activities	—	6,356,000 EUR	—	—	11,483,000 EUR	—	—
Purchase of intangible assets, classified as investing activities	—	19,302,000 EUR	—	—	9,699,000 EUR	—	—
Cash flows from (used in) investing activities	—	25,490,000 EUR	—	—	54,682,000 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities	—	6,663,000 EUR	—	—	7,193,000 EUR	—	—
Proceeds from government grants, classified as financing activities	—	154,000 EUR	—	—	41,000 EUR	—	—
Interest paid, classified as financing activities	—	9,862,000 EUR	—	—	9,364,000 EUR	—	—
Cash flows from (used in) financing activities	—	77,869,000 EUR	—	—	25,646,000 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	147,000 EUR	—	—	21,000 EUR	—	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	4,440,000 EUR	—	—	105,824,000 EUR	—	—
Cash and cash equivalents	28,285,000 EUR	—	—	32,872,000 EUR	—	—	138,675,000 EUR